Gut Microbiota, Immunity, and Bile Acid Metabolism: Decoding Metabolic Disease Interactions

Overview

Journal Life Metab

Publisher Oxford University Press

Date 2025 Jan 28

PMID 39872860

Authors

Qixiang Zhao

Jiayu Wu

Yong Ding

Yanli Pang

Changtao Jiang

Affiliations

Soon will be listed here.

Abstract

In recent decades, the global prevalence of metabolic syndrome has surged, posing a significant public health challenge. Metabolic disorders, encompassing diabetes, obesity, nonalcoholic fatty liver disease, and polycystic ovarian syndrome, have been linked to alterations in the gut microbiota. Nonetheless, the connection between gut microbiota and host metabolic diseases warrants further investigation. In this review, we delve into the associations between various metabolic disorders and the gut microbiota, focusing on immune responses and bile acid (BA) metabolism. Notably, T helper cells, innate lymphoid cells, macrophages, and dendritic cells have been shown to modulate host metabolism through interactions with intestinal microorganisms and the release of cytokines. Furthermore, secondary BA metabolites, derived from the microbiota, are involved in the pathogenesis of metabolic diseases via the farnesoid X receptor and Takeda G protein-coupled receptor 5. By covering both aspects of this immune system-microorganism axis, we present a comprehensive overview of the roles played by the gut microbiota, microbiota-derived BA metabolites, and immune responses in metabolic diseases, as well as the interplay between these systems.

References

Galle-Treger L, Helou D, Quach C, Howard E, Hurrell B, Aleman Muench G . Autophagy impairment in liver CD11c cells promotes non-alcoholic fatty liver disease through production of IL-23. Nat Commun. 2022; 13(1):1440. PMC: 8931085. DOI: 10.1038/s41467-022-29174-y. View

Shi Z, Lei H, Chen G, Yuan P, Cao Z, Ser H . Impaired Intestinal Akkermansia muciniphila and Aryl Hydrocarbon Receptor Ligands Contribute to Nonalcoholic Fatty Liver Disease in Mice. mSystems. 2021; 6(1). PMC: 8573958. DOI: 10.1128/mSystems.00985-20. View

Rahman K, Desai C, Iyer S, Thorn N, Kumar P, Liu Y . Loss of Junctional Adhesion Molecule A Promotes Severe Steatohepatitis in Mice on a Diet High in Saturated Fat, Fructose, and Cholesterol. Gastroenterology. 2016; 151(4):733-746.e12. PMC: 5037035. DOI: 10.1053/j.gastro.2016.06.022. View

Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L . A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med. 2016; 23(1):107-113. DOI: 10.1038/nm.4236. View

James K, Gomes T, Elmentaite R, Kumar N, Gulliver E, King H . Distinct microbial and immune niches of the human colon. Nat Immunol. 2020; 21(3):343-353. PMC: 7212050. DOI: 10.1038/s41590-020-0602-z. View

Guo Y, Qi Y, Yang X, Zhao L, Wen S, Liu Y . Association between Polycystic Ovary Syndrome and Gut Microbiota. PLoS One. 2016; 11(4):e0153196. PMC: 4836746. DOI: 10.1371/journal.pone.0153196. View

Shalon D, Culver R, Grembi J, Folz J, Treit P, Shi H . Profiling the human intestinal environment under physiological conditions. Nature. 2023; 617(7961):581-591. PMC: 10191855. DOI: 10.1038/s41586-023-05989-7. View

Nakajima A, Seki M, Taniguchi S, Ohta A, Gillberg P, Mattsson J . Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. Lancet Gastroenterol Hepatol. 2018; 3(8):537-547. DOI: 10.1016/S2468-1253(18)30123-7. View

Zuniga L, Shen W, Joyce-Shaikh B, Pyatnova E, Richards A, Thom C . IL-17 regulates adipogenesis, glucose homeostasis, and obesity. J Immunol. 2010; 185(11):6947-59. PMC: 3001125. DOI: 10.4049/jimmunol.1001269. View

10.

Oh T, Kim S, Caussy C, Fu T, Guo J, Bassirian S . A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis. Cell Metab. 2020; 32(5):901. PMC: 7891106. DOI: 10.1016/j.cmet.2020.10.015. View

11.

Sun L, Pang Y, Wang X, Wu Q, Liu H, Liu B . Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters. Acta Pharm Sin B. 2019; 9(4):702-710. PMC: 6664038. DOI: 10.1016/j.apsb.2019.02.004. View

12.

Traussnigg S, Schattenberg J, Demir M, Wiegand J, Geier A, Teuber G . Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. Lancet Gastroenterol Hepatol. 2019; 4(10):781-793. DOI: 10.1016/S2468-1253(19)30184-0. View

13.

Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C . A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 2010; 54(5):1011-9. DOI: 10.1016/j.jhep.2010.08.030. View

14.

Lindheim L, Bashir M, Munzker J, Trummer C, Zachhuber V, Leber B . Alterations in Gut Microbiome Composition and Barrier Function Are Associated with Reproductive and Metabolic Defects in Women with Polycystic Ovary Syndrome (PCOS): A Pilot Study. PLoS One. 2017; 12(1):e0168390. PMC: 5207627. DOI: 10.1371/journal.pone.0168390. View

15.

Yang J, Li Y, Wen Z, Liu W, Meng L, Huang H . Oscillospira - a candidate for the next-generation probiotics. Gut Microbes. 2021; 13(1):1987783. PMC: 8547878. DOI: 10.1080/19490976.2021.1987783. View

16.

Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A . Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med. 2009; 15(8):930-9. PMC: 3115752. DOI: 10.1038/nm.2002. View

17.

Matsubara T, Li F, Gonzalez F . FXR signaling in the enterohepatic system. Mol Cell Endocrinol. 2012; 368(1-2):17-29. PMC: 3491147. DOI: 10.1016/j.mce.2012.05.004. View

18.

Kastl Jr A, Terry N, Wu G, Albenberg L . The Structure and Function of the Human Small Intestinal Microbiota: Current Understanding and Future Directions. Cell Mol Gastroenterol Hepatol. 2019; 9(1):33-45. PMC: 6881639. DOI: 10.1016/j.jcmgh.2019.07.006. View

19.

Cani P, Bibiloni R, Knauf C, Waget A, Neyrinck A, Delzenne N . Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008; 57(6):1470-81. DOI: 10.2337/db07-1403. View

20.

Depommier C, Everard A, Druart C, Plovier H, Van Hul M, Vieira-Silva S . Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019; 25(7):1096-1103. PMC: 6699990. DOI: 10.1038/s41591-019-0495-2. View